FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324151908> ?p ?o ?g. }

• W2324151908 endingPage "1273" @default.
• W2324151908 startingPage "1264" @default.
• W2324151908 abstract "Purpose The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Materials and Methods Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinicolaboratory factors, univariate and multivariable analyses for overall survival (OS) were performed. Results A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11 to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic disease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.36; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. Conclusion Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials. Key words: Pancreatic neoplasms, Gemcitabine, Drug therapy, Sarcopenia, Prognosis" @default.
• W2324151908 created "2016-06-24" @default.
• W2324151908 creator A5001297228 @default.
• W2324151908 creator A5007931207 @default.
• W2324151908 creator A5014222628 @default.
• W2324151908 creator A5043919045 @default.
• W2324151908 creator A5044268319 @default.
• W2324151908 creator A5049643415 @default.
• W2324151908 creator A5055097851 @default.
• W2324151908 creator A5067482196 @default.
• W2324151908 creator A5076115706 @default.
• W2324151908 creator A5083074248 @default.
• W2324151908 creator A5087043789 @default.
• W2324151908 date "2016-10-15" @default.
• W2324151908 modified "2023-10-11" @default.
• W2324151908 title "Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy" @default.
• W2324151908 cites W1931508686 @default.
• W2324151908 cites W1979603074 @default.
• W2324151908 cites W1996472967 @default.
• W2324151908 cites W2000066547 @default.
• W2324151908 cites W2009289441 @default.
• W2324151908 cites W2010341706 @default.
• W2324151908 cites W2016341941 @default.
• W2324151908 cites W2036610278 @default.
• W2324151908 cites W2040046366 @default.
• W2324151908 cites W2040291607 @default.
• W2324151908 cites W2081612215 @default.
• W2324151908 cites W2101398993 @default.
• W2324151908 cites W2102902846 @default.
• W2324151908 cites W2104969468 @default.
• W2324151908 cites W2107089530 @default.
• W2324151908 cites W2115150337 @default.
• W2324151908 cites W2118558111 @default.
• W2324151908 cites W2145280166 @default.
• W2324151908 cites W2151253787 @default.
• W2324151908 cites W2158134441 @default.
• W2324151908 cites W2165480504 @default.
• W2324151908 cites W2169244250 @default.
• W2324151908 cites W2223801424 @default.
• W2324151908 cites W2406676626 @default.
• W2324151908 cites W2917837889 @default.
• W2324151908 cites W2917869996 @default.
• W2324151908 cites W4244578979 @default.
• W2324151908 doi "https://doi.org/10.4143/crt.2015.250" @default.
• W2324151908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5080812" @default.
• W2324151908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27034148" @default.
• W2324151908 hasPublicationYear "2016" @default.
• W2324151908 type Work @default.
• W2324151908 sameAs 2324151908 @default.
• W2324151908 citedByCount "37" @default.
• W2324151908 countsByYear W23241519082017 @default.
• W2324151908 countsByYear W23241519082018 @default.
• W2324151908 countsByYear W23241519082019 @default.
• W2324151908 countsByYear W23241519082020 @default.
• W2324151908 countsByYear W23241519082021 @default.
• W2324151908 countsByYear W23241519082022 @default.
• W2324151908 countsByYear W23241519082023 @default.
• W2324151908 crossrefType "journal-article" @default.
• W2324151908 hasAuthorship W2324151908A5001297228 @default.
• W2324151908 hasAuthorship W2324151908A5007931207 @default.
• W2324151908 hasAuthorship W2324151908A5014222628 @default.
• W2324151908 hasAuthorship W2324151908A5043919045 @default.
• W2324151908 hasAuthorship W2324151908A5044268319 @default.
• W2324151908 hasAuthorship W2324151908A5049643415 @default.
• W2324151908 hasAuthorship W2324151908A5055097851 @default.
• W2324151908 hasAuthorship W2324151908A5067482196 @default.
• W2324151908 hasAuthorship W2324151908A5076115706 @default.
• W2324151908 hasAuthorship W2324151908A5083074248 @default.
• W2324151908 hasAuthorship W2324151908A5087043789 @default.
• W2324151908 hasBestOaLocation W23241519081 @default.
• W2324151908 hasConcept C121608353 @default.
• W2324151908 hasConcept C126322002 @default.
• W2324151908 hasConcept C143998085 @default.
• W2324151908 hasConcept C144301174 @default.
• W2324151908 hasConcept C207103383 @default.
• W2324151908 hasConcept C2776214593 @default.
• W2324151908 hasConcept C2776694085 @default.
• W2324151908 hasConcept C2777387746 @default.
• W2324151908 hasConcept C2780210213 @default.
• W2324151908 hasConcept C2780258809 @default.
• W2324151908 hasConcept C38180746 @default.
• W2324151908 hasConcept C44249647 @default.
• W2324151908 hasConcept C71924100 @default.
• W2324151908 hasConcept C90924648 @default.
• W2324151908 hasConceptScore W2324151908C121608353 @default.
• W2324151908 hasConceptScore W2324151908C126322002 @default.
• W2324151908 hasConceptScore W2324151908C143998085 @default.
• W2324151908 hasConceptScore W2324151908C144301174 @default.
• W2324151908 hasConceptScore W2324151908C207103383 @default.
• W2324151908 hasConceptScore W2324151908C2776214593 @default.
• W2324151908 hasConceptScore W2324151908C2776694085 @default.
• W2324151908 hasConceptScore W2324151908C2777387746 @default.
• W2324151908 hasConceptScore W2324151908C2780210213 @default.
• W2324151908 hasConceptScore W2324151908C2780258809 @default.
• W2324151908 hasConceptScore W2324151908C38180746 @default.
• W2324151908 hasConceptScore W2324151908C44249647 @default.
• W2324151908 hasConceptScore W2324151908C71924100 @default.
• W2324151908 hasConceptScore W2324151908C90924648 @default.

• next